Sanofi to invest €300m in Innovent Biologics.

Sanofi, a global healthcare company, agreed to invest €300m in Innovent Biologics, a biopharmaceutical company. "This strategic collaboration with Innovent will not only accelerate the development, market access and future commercialization of two of our key oncology medicines in selected combinations with sintilimab, but also bolster our overall presence in oncology in China. We look forward to a successful partnership with Innovent, one of the most innovative companies in China, and to leveraging their development capabilities and market leadership in the country," John Reed, Sanofi Global Head of Research and Development.